<p>Cypress Capital Group 在第二季度增持了 Quest Diagnostics Incorporated（NYSE:DGX - 免費報告）的持股，根據該公司最近向 SEC 提交的文件，持股增長了 75.4%。該基金在本季度購買了額外的 1,648 股，持有這家醫療研究公司的 3,834 股股票。Cypress Capital Group 在最新報告期結束時持有的 Quest Diagnostics 股票價值為$525,000。</p>
<p>獲取 <strong>Quest Diagnostics</strong> 警報：</p>
<ul>
<li>Myriad Genetics 通過遺傳癌症檢測看到股價飆升</li>
</ul>
<p>其他一些大型投資者最近也增加或減少了對該公司的持股。路易斯安那州僱員退休系統在第四季度收購了 Quest Diagnostics 股票的新股份，價值約為$938,000。Lindbrook Capital LLC 在第四季度增持了 Quest Diagnostics 的股份，持股增長了 120.7%。Lindbrook Capital LLC 現在擁有 415 股這家醫療研究公司股票，價值$57,000，比上一季度多購買了 227 股。Signaturefd LLC 在第四季度增持了 Quest Diagnostics 的股份，持股增長了 43.7%。Signaturefd LLC 現在擁有 1,374 股這家醫療研究公司股票，價值$189,000，期間又購買了 418 股。CWM LLC 在第四季度增加了對 Quest Diagnostics 的持股，持股增長了 1.3%。CWM LLC 現在擁有 18,200 股這家醫療研究公司股票，價值$2,509,000，比上一季度多購買了 232 股。最後，GAMMA Investing LLC 在第四季度收購了 Quest Diagnostics 的新股份，價值$67,000。該股票的 88.06% 由機構投資者持有。</p>
<h2>分析師評級變動</h2>
<p>DGX 已成為多家研究分析師報告的主題。StockNews.com 在 7 月 23 日星期二的研究報告中，將 Quest Diagnostics 的股票評級從 “持有” 調升至 “買入”。Piper Sandler 將 Quest Diagnostics 的價格目標從$145.00 上調至$150.00，並給予股票 “中性” 評級。Truist Financial 將 Quest Diagnostics 的目標價從$150.00 上調至$158.00，並在 7 月 15 日星期一的研究報告中給予該公司 “持有” 評級。Robert W. Baird 將 Quest Diagnostics 的目標價從$153.00 上調至$154.00，並在 7 月 24 日星期三的研究報告中給予股票 “中性” 評級。最後，摩根大通將 Quest Diagnostics 的目標價從$152.00 上調至$155.00，並在 5 月 30 日星期四的研究報告中給予該公司 “中性” 評級。八位投資分析師對該股票給予持有評級，五位對該公司股票給予買入評級。根據 MarketBeat，該股票目前的共識評級為 “持有”，共識目標價為$150.58。</p>
<p><strong>閲讀我們對 Quest Diagnostics 的最新分析</strong></p>
<h2>Quest Diagnostics 股票表現</h2>
<p>週一交易時間，DGX 股票上漲$0.69，達到$154.25。該股票的交易量為 79,501 股，相比平均交易量 967,391 股。該股票的 50 天簡單移動平均線為$144.29，200 天簡單移動平均線為$137.03。Quest Diagnostics Incorporated 的 52 周最低價為$119.59，52 周最高價為$154.71。該股票的市值為 171.4 億美元，市盈率為 20.67，市盈增長比為 2.69，β係數為 0.89。該公司的資產負債比為 0.57，流動比率為 1.00，速動比率為 0.91。</p>
<p>Quest Diagnostics（NYSE:DGX - 獲取免費報告）最近公佈了其季度收益報告，報告日期為 7 月 23 日星期二。這家醫療研究公司在該季度報告中每股盈利為$2.35，超過了分析師預期的$2.31。該季度業務收入為 24 億美元，超過了分析師對 23.9 億美元的預期。Quest Diagnostics 的淨資產回報率為 15.35%，淨利潤率為 8.99%。該季度公司的收入同比增長了 2.5%。在去年同期的同一季度，該公司每股盈利為$2.30。分析師預測，Quest Diagnostics Incorporated 本財年的每股盈利將達到 8.89 美元。</p>
<h2>Quest Diagnostics 股息宣佈</h2>
<p>該公司最近宣佈了季度股息，將於 10 月 21 日星期一支付。截至 10 月 4 日星期五持股的股東將獲得 0.75 美元的股息。這代表每年 3.00 美元的股息和 1.94% 的股息率。除權日為 10 月 4 日星期五。Quest Diagnostics 的派息比率為 40.38%。</p>
<h2>Quest Diagnostics 內部交易</h2>
<p>在其他 Quest Diagnostics 的消息中，高級副總裁 Mark E. Delaney 於 7 月 24 日星期三進行了一筆交易，賣出了 420 股 Quest Diagnostics 股票。這些股票的平均價格為$143.08，總價值為$60,093.60。交易完成後，這位高級副總裁在公司中持有 5,019 股股票，價值約為$718,118.52。該交易已在證券交易委員會的備案中披露，可通過 SEC 網站查看。公司股份的 0.79% 由公司內部持有。</p>
<h2>Quest Diagnostics 簡介（免費報告）</h2>
<p>Quest Diagnostics Incorporated 在美國和國際上提供診斷測試和服務。該公司開發並提供診斷信息服務，包括常規、非常規和高級臨牀測試、解剖病理測試和其他診斷信息服務。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們比藥明康德更喜歡的股票</li>
<li>如何計算投資回報率（ROI）</li>
<li>艾禮莉的通往下一個萬億市值之路</li>
<li>內部人士出售解讀：能指導你的投資選擇嗎？</li>
<li>Mobileye Global：CEO 對未來實力押注 1000 萬美元</li>
<li>交通運輸股投資</li>
<li>3 家公司在降息之前增加股息支付</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURHWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURHWA"/></p>
<p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速、最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<p>→ 擁有的 3 只股息股票（來自 DTI）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTc3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTc3"/></p>
<h2>現在是否值得投資 1000 美元購買藥明康德？</h2>
<p>在考慮藥明康德之前，您需要聽到這個消息。</p>
<p>MarketBeat 追蹤華爾街評級最高、表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户現在購買的股票，而藥明康德不在名單上。</p>
<p>儘管藥明康德目前在分析師中有一個 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

奎斯特診療

<p>Cypress Capital Group 在第二季度增持了 Quest Diagnostics（紐約證券交易所：DGX）的持股，增幅為 75.4%，增持了 1,648 股，使其持股總數達到 3,834 股。其他幾家機構也調整了他們在該公司的持股。Quest Diagnostics 的股票目前在分析師中有共識的 “持有” 評級，目標股價為 66.58 美元。該公司第二季度每股盈利為 1.35 美元，超過了預期，並宣佈每股 0.75 美元的季度股息，將於 10 月 21 日支付</p>

<p>Cypress Capital Group lifted its position in Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 75.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 3,834 shares of the medical research company's stock after purchasing an additional 1,648 shares during the quarter. Cypress Capital Group's holdings in Quest Diagnostics were worth $525,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Cypress Capital Group 在第二季度增持了 Quest Diagnostics Incorporated（NYSE:DGX - 免費報告）的持股，根據該公司最近向 SEC 提交的文件，持股增長了 75.4%。該基金在本季度購買了額外的 1,648 股，持有這家醫療研究公司的 3,834 股股票。Cypress Capital Group 在最新報告期結束時持有的 Quest Diagnostics 股票價值為$525,000。</p>
</div><p>Get <strong>Quest Diagnostics</strong> alerts:</p>
<ul>
<li>Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests</li>
</ul>
<div class="lb-trans"><p>獲取 <strong>Quest Diagnostics</strong> 警報：</p>
<ul>
<li>Myriad Genetics 通過遺傳癌症檢測看到股價飆升</li>
</ul>
</div><p>Several other large investors have also recently added to or reduced their stakes in the company. Louisiana State Employees Retirement System acquired a new stake in shares of Quest Diagnostics in the fourth quarter valued at approximately $938,000. Lindbrook Capital LLC lifted its holdings in shares of Quest Diagnostics by 120.7% during the 4th quarter. Lindbrook Capital LLC now owns 415 shares of the medical research company's stock valued at $57,000 after purchasing an additional 227 shares in the last quarter. Signaturefd LLC boosted its holdings in shares of Quest Diagnostics by 43.7% in the fourth quarter. Signaturefd LLC now owns 1,374 shares of the medical research company's stock valued at $189,000 after buying an additional 418 shares during the period. CWM LLC increased its position in shares of Quest Diagnostics by 1.3% during the fourth quarter. CWM LLC now owns 18,200 shares of the medical research company's stock worth $2,509,000 after acquiring an additional 232 shares in the last quarter. Finally, GAMMA Investing LLC acquired a new stake in shares of Quest Diagnostics during the fourth quarter worth $67,000. 88.06% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些大型投資者最近也增加或減少了對該公司的持股。路易斯安那州僱員退休系統在第四季度收購了 Quest Diagnostics 股票的新股份，價值約為$938,000。Lindbrook Capital LLC 在第四季度增持了 Quest Diagnostics 的股份，持股增長了 120.7%。Lindbrook Capital LLC 現在擁有 415 股這家醫療研究公司股票，價值$57,000，比上一季度多購買了 227 股。Signaturefd LLC 在第四季度增持了 Quest Diagnostics 的股份，持股增長了 43.7%。Signaturefd LLC 現在擁有 1,374 股這家醫療研究公司股票，價值$189,000，期間又購買了 418 股。CWM LLC 在第四季度增加了對 Quest Diagnostics 的持股，持股增長了 1.3%。CWM LLC 現在擁有 18,200 股這家醫療研究公司股票，價值$2,509,000，比上一季度多購買了 232 股。最後，GAMMA Investing LLC 在第四季度收購了 Quest Diagnostics 的新股份，價值$67,000。該股票的 88.06% 由機構投資者持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>DGX has been the subject of a number of research analyst reports. StockNews.com raised shares of Quest Diagnostics from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Tuesday, July 23rd. Piper Sandler increased their price objective on Quest Diagnostics from $145.00 to $150.00 and gave the stock a &#34;neutral&#34; rating in a report on Monday, July 29th. Truist Financial boosted their target price on Quest Diagnostics from $150.00 to $158.00 and gave the company a &#34;hold&#34; rating in a research note on Monday, July 15th. Robert W. Baird upped their price target on Quest Diagnostics from $153.00 to $154.00 and gave the stock a &#34;neutral&#34; rating in a research report on Wednesday, July 24th. Finally, JPMorgan Chase &amp; Co. lifted their price objective on shares of Quest Diagnostics from $152.00 to $155.00 and gave the company a &#34;neutral&#34; rating in a report on Thursday, May 30th. Eight investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of &#34;Hold&#34; and a consensus target price of $150.58.</p>
<ul>
<li>LifeMD Shares Come Back to Life on GLP-1 Business Growth</li>
</ul>
<div class="lb-trans"><p>DGX 已成為多家研究分析師報告的主題。StockNews.com 在 7 月 23 日星期二的研究報告中，將 Quest Diagnostics 的股票評級從 “持有” 調升至 “買入”。Piper Sandler 將 Quest Diagnostics 的價格目標從$145.00 上調至$150.00，並給予股票 “中性” 評級。Truist Financial 將 Quest Diagnostics 的目標價從$150.00 上調至$158.00，並在 7 月 15 日星期一的研究報告中給予該公司 “持有” 評級。Robert W. Baird 將 Quest Diagnostics 的目標價從$153.00 上調至$154.00，並在 7 月 24 日星期三的研究報告中給予股票 “中性” 評級。最後，摩根大通將 Quest Diagnostics 的目標價從$152.00 上調至$155.00，並在 5 月 30 日星期四的研究報告中給予該公司 “中性” 評級。八位投資分析師對該股票給予持有評級，五位對該公司股票給予買入評級。根據 MarketBeat，該股票目前的共識評級為 “持有”，共識目標價為$150.58。</p>
</div><p><strong>Read Our Latest Analysis on Quest Diagnostics</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 Quest Diagnostics 的最新分析</strong></p>
</div><h2>Quest Diagnostics Stock Performance</h2>
<div class="lb-trans"><h2>Quest Diagnostics 股票表現</h2>
</div><p>DGX stock traded up $0.69 during trading hours on Monday, reaching $154.25. The stock had a trading volume of 79,501 shares, compared to its average volume of 967,391. The stock has a 50-day simple moving average of $144.29 and a 200 day simple moving average of $137.03. Quest Diagnostics Incorporated has a fifty-two week low of $119.59 and a fifty-two week high of $154.71. The stock has a market capitalization of $17.14 billion, a PE ratio of 20.67, a price-to-earnings-growth ratio of 2.69 and a beta of 0.89. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.00 and a quick ratio of 0.91.</p>
<ul>
<li>Exact Sciences Serves Investors Exactly What They Wished For</li>
</ul>
<div class="lb-trans"><p>週一交易時間，DGX 股票上漲$0.69，達到$154.25。該股票的交易量為 79,501 股，相比平均交易量 967,391 股。該股票的 50 天簡單移動平均線為$144.29，200 天簡單移動平均線為$137.03。Quest Diagnostics Incorporated 的 52 周最低價為$119.59，52 周最高價為$154.71。該股票的市值為 171.4 億美元，市盈率為 20.67，市盈增長比為 2.69，β係數為 0.89。該公司的資產負債比為 0.57，流動比率為 1.00，速動比率為 0.91。</p>
</div><p>Quest Diagnostics (NYSE:DGX - Get Free Report) last posted its quarterly earnings results on Tuesday, July 23rd. The medical research company reported $2.35 earnings per share for the quarter, beating analysts' consensus estimates of $2.31 by $0.04. The business had revenue of $2.40 billion for the quarter, compared to analysts' expectations of $2.39 billion. Quest Diagnostics had a return on equity of 15.35% and a net margin of 8.99%. The firm's revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.30 EPS. Analysts predict that Quest Diagnostics Incorporated will post 8.89 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Quest Diagnostics（NYSE:DGX - 獲取免費報告）最近公佈了其季度收益報告，報告日期為 7 月 23 日星期二。這家醫療研究公司在該季度報告中每股盈利為$2.35，超過了分析師預期的$2.31。該季度業務收入為 24 億美元，超過了分析師對 23.9 億美元的預期。Quest Diagnostics 的淨資產回報率為 15.35%，淨利潤率為 8.99%。該季度公司的收入同比增長了 2.5%。在去年同期的同一季度，該公司每股盈利為$2.30。分析師預測，Quest Diagnostics Incorporated 本財年的每股盈利將達到 8.89 美元。</p>
</div><h2>Quest Diagnostics Dividend Announcement</h2>
<div class="lb-trans"><h2>Quest Diagnostics 股息宣佈</h2>
</div><p>The company also recently announced a quarterly dividend, which will be paid on Monday, October 21st. Stockholders of record on Friday, October 4th will be given a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 1.94%. The ex-dividend date is Friday, October 4th. Quest Diagnostics's payout ratio is 40.38%.</p>
<div class="lb-trans"><p>該公司最近宣佈了季度股息，將於 10 月 21 日星期一支付。截至 10 月 4 日星期五持股的股東將獲得 0.75 美元的股息。這代表每年 3.00 美元的股息和 1.94% 的股息率。除權日為 10 月 4 日星期五。Quest Diagnostics 的派息比率為 40.38%。</p>
</div><h2>Insider Transactions at Quest Diagnostics</h2>
<div class="lb-trans"><h2>Quest Diagnostics 內部交易</h2>
</div><p>In other Quest Diagnostics news, SVP Mark E. Delaney sold 420 shares of Quest Diagnostics stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $143.08, for a total value of $60,093.60. Following the completion of the sale, the senior vice president now owns 5,019 shares in the company, valued at approximately $718,118.52. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through the SEC website. 0.79% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 Quest Diagnostics 的消息中，高級副總裁 Mark E. Delaney 於 7 月 24 日星期三進行了一筆交易，賣出了 420 股 Quest Diagnostics 股票。這些股票的平均價格為$143.08，總價值為$60,093.60。交易完成後，這位高級副總裁在公司中持有 5,019 股股票，價值約為$718,118.52。該交易已在證券交易委員會的備案中披露，可通過 SEC 網站查看。公司股份的 0.79% 由公司內部持有。</p>
</div><h2>Quest Diagnostics Profile (Free Report)</h2>
<div class="lb-trans"><h2>Quest Diagnostics 簡介（免費報告）</h2>
</div><p>Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.</p>
<div class="lb-trans"><p>Quest Diagnostics Incorporated 在美國和國際上提供診斷測試和服務。該公司開發並提供診斷信息服務，包括常規、非常規和高級臨牀測試、解剖病理測試和其他診斷信息服務。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Quest Diagnostics</li>
<li>How to Calculate Return on Investment (ROI)</li>
<li>Eli Lilly’s Path to the Next Trillion Market Capitalization</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>Mobileye Global: CEO Makes $10 Million Bet on Future Strength</li>
<li>Transportation Stocks Investing</li>
<li>3 Stocks Increasing Dividend Payouts Ahead of Interest Rate Cuts</li>
</ul>
<div class="lb-trans"><h2>精選故事</h2>
<ul>
<li>五隻我們比藥明康德更喜歡的股票</li>
<li>如何計算投資回報率（ROI）</li>
<li>艾禮莉的通往下一個萬億市值之路</li>
<li>內部人士出售解讀：能指導你的投資選擇嗎？</li>
<li>Mobileye Global：CEO 對未來實力押注 1000 萬美元</li>
<li>交通運輸股投資</li>
<li>3 家公司在降息之前增加股息支付</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURHWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=DGX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速、最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><p>→ 3 dividend stocks to own (From DTI)(Ad)</p>
<div class="lb-trans"><p>→ 擁有的 3 只股息股票（來自 DTI）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTc3" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8977&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Quest Diagnostics right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資 1000 美元購買藥明康德？</h2>
</div><p>Before you consider Quest Diagnostics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮藥明康德之前，您需要聽到這個消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quest Diagnostics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高、表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户現在購買的股票，而藥明康德不在名單上。</p>
</div><p>While Quest Diagnostics currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管藥明康德目前在分析師中有一個 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

賽普拉斯資本集團收購了奎斯特診療公司（NYSE:DGX）的 1,648 股股票